Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (MOVE) pioneers wearable health technology that transforms personal wellness through medical-grade data collection. This page aggregates official announcements, financial updates, and strategic developments from the creator of the Evie Ring—a women-focused wearable tracking metabolic health indicators like glucose trends and heart rate variability.
Investors and industry observers will find curated press releases covering product launches, FDA clearances, and enterprise partnerships. Key updates include earnings reports, clinical validation milestones, and expansions into chronic disease management markets. All content is vetted for accuracy and relevance to health tech innovation.
Bookmark this page for streamlined access to Movano's evolving role in bridging consumer wearables with clinical insights. Check regularly for developments in sensor technology advancements and new applications of its AI-driven health analytics platform.
Movano Health (Nasdaq: MOVE) announced a proposed underwritten public offering of shares and warrants to purchase common stock. The offering will be conducted by the company, which aims to grant the underwriter a 30-day option for an additional 15% of shares. Proceeds will support general corporate purposes, including product development and commercialization. Newbridge Securities Corporation is the sole book-running manager for the offering. The final terms are subject to market conditions, and the offering will be registered with the SEC. The company cautions that actual results may vary due to inherent risks and uncertainties.
Movano Health (Nasdaq: MOVE) plans to file for FDA clearance for its new women-focused wearable, the Evie smart ring, which integrates medical-grade health data into a user-friendly mobile app. Designed to enhance women's health insights, Evie will provide metrics including heart rate, SpO2, and menstrual tracking, aiming to empower users to make informed health decisions without a subscription fee. Following a successful hypoxia trial confirming accuracy, Evie is set to debut at CES 2023, priced below $300 and available in 2023.
Movano Health (NASDAQ: MOVE) announced promising preliminary results from its pivotal hypoxia trial, demonstrating a 2% margin of error for blood oxygen saturation (SpO2) and a heart rate error of 2 BPM. Both metrics exceeded FDA standards, indicating high accuracy. The trial involved 11 subjects and followed an FDA-required protocol. Movano plans to file for FDA clearance in 2023. CEO John Mastrototaro emphasized the importance of developing wearable devices that empower consumers with reliable health data.
Movano Health has initiated a beta program for its smart ring, designed to track and analyze medical-grade data, in collaboration with Novant Health. Approximately 30 team members from Novant will assess the smart ring's functionality and wearability. The beta program, set to commence this month, aims to prepare Movano for its product launch targeted for the first half of 2023. The collaboration underscores a shared goal of making healthcare more accessible and could provide vital feedback for Movano's technology development in consumer health.
Movano Health (Nasdaq: MOVE) announced participation in several investor-focused events to discuss progress on its smart ring and an integrated circuit for blood pressure and glucose monitoring. Upcoming events include the Bernstein CGM Disruptors Conference on November 18, 2022, the BTIG Digital Health Forum on November 21, 2022, and the Benchmark Discovery Conference on December 1, 2022. These invite-only conferences aim to connect with clients and stakeholders. For more information, visit movanohealth.com.
Movano Inc. (NASDAQ:MOVE) reported Q3 2022 financial results, showing a net loss of $8.6 million, or $(0.26) per share, up from a loss of $5.2 million in Q3 2021. The company will begin beta testing its smart wearables with Stanford University and Novant Health, aiming for FDA approval in early 2023. Movano has $16.8 million in cash, a decrease from $33.6 million at the end of 2021. Additionally, it plans to initiate blood pressure and glucose studies by year-end 2022. The conference call discussing these results is scheduled for today at 2:00 p.m. PST.
Movano Inc. (NASDAQ: MOVE) will report its third quarter 2022 financial results on November 14, 2022. A conference call and live audio webcast will take place at 2:00 p.m. PDT to discuss these results and provide business updates. The company's focus is on developing healthcare solutions that integrate medical-grade data into consumer devices, aiming to help users proactively manage their health. Movano emphasizes its commitment to innovation within the medtech industry.
Movano Inc. (NASDAQ:MOVE) announced its Q2 2022 financial results, reporting a net loss of $6.9 million, compared to $4.7 million in Q2 2021. The company has initiated beta testing programs for its Movano Ring with partners like Stanford University, targeting a direct-to-consumer launch in H1 2023. Recent studies demonstrated the Ring's accuracy in measuring blood oxygen and heart rate, crucial for FDA submission. Movano also plans further clinical studies on blood pressure and glucose monitoring using its patented system-on-a-chip technology. The company held $21.3 million in cash as of June 30, 2022.
FAQ
What is the current stock price of Movano (MOVE)?
What is the market cap of Movano (MOVE)?
